KRAS-ERK switch could revive chemotherapy response in pancreatic cancer
TL;DR Summary
Researchers identify a KRAS/ERK/JUNB signaling axis that suppresses the differentiation regulator GATA6, pushing pancreatic tumors from a classical, chemo‑sensitive state to a basal, chemo‑resistant one; inhibiting this pathway raises GATA6 levels, reverting cells to a more treatable state and enhancing the effectiveness of standard chemotherapy when paired with targeted therapies.
- Breakthrough Discovery Could Make Pancreatic Cancer Respond to Chemo Again SciTechDaily
- Scientists find the genetic switch that makes pancreatic cancer resist chemotherapy ScienceDaily
- Melvin Sanicas: How GATA6 Levels Influence Treatment Response in Pancreatic Cancer Oncodaily
- A graphical abstract of the paper’s findings (IMAGE) EurekAlert!
- Scientists uncover molecular ‘switch’ that could make pancreatic cancer more treatable Asia Research News |
Reading Insights
Total Reads
0
Unique Readers
11
Time Saved
5 min
vs 5 min read
Condensed
95%
976 → 50 words
Want the full story? Read the original article
Read on SciTechDaily